Collegium Pharmaceutical (COLL) FDA Approvals $34.80 +0.40 (+1.16%) Closing price 04:00 PM EasternExtended Trading$34.83 +0.03 (+0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Collegium Pharmaceutical's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Collegium Pharmaceutical (COLL). Over the past two years, Collegium Pharmaceutical has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Jornay. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Jornay PM FDA Regulatory Events Jornay PM is a drug developed by Collegium Pharmaceutical for the following indication: for the treatment of attention deficit hyperactivity disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Poster Presentation - October 22,2025Poster Presentation Drug: Jornay PMAnnounced Date: October 22, 2025Indication: for the treatment of attention deficit hyperactivity disorderAnnouncementCollegium Pharmaceutical, Inc announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neuroscience Education Institute (NEI) conferences.AI SummaryCollegium Pharmaceutical will present real-world data on its ADHD product Jornay PM at two conferences. One poster will appear at the American Academy of Child & Adolescent Psychiatry in Chicago (Oct 20–25). The other will be shown at the Neuroscience Education Institute Fall Congress in Colorado Springs (Nov 6–9). The AACAP poster explores optimal dosing of methylphenidate in adolescents and adults in real-world psychiatric settings. The NEI poster examines how patients use and respond to Jornay PM outside clinical trials. Thomas Smith, M.D., said these findings during ADHD Awareness Month highlight Collegium’s commitment to improving care. Researchers will share insights on dosing and patient response to this unique nighttime ADHD stimulant. The AACAP poster will be shown Oct 22, 4–6 p.m. CDT at the Hyatt Regency, and the NEI poster will be presented Nov 7, 4–5 p.m. MST at Broadmoor West.Read Announcement Collegium Pharmaceutical FDA Events - Frequently Asked Questions Has Collegium Pharmaceutical received FDA approval? As of now, Collegium Pharmaceutical (COLL) has not received any FDA approvals for its therapy in the last two years. What drugs has Collegium Pharmaceutical submitted to the FDA? In the past two years, Collegium Pharmaceutical (COLL) has reported FDA regulatory activity for Jornay PM. What is the most recent FDA event for Collegium Pharmaceutical? The most recent FDA-related event for Collegium Pharmaceutical occurred on October 22, 2025, involving Jornay PM. The update was categorized as "Poster Presentation," with the company reporting: "Collegium Pharmaceutical, Inc announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neuroscience Education Institute (NEI) conferences." What conditions do Collegium Pharmaceutical's current drugs treat? Currently, Collegium Pharmaceutical has one therapy (Jornay PM) targeting the following condition: for the treatment of attention deficit hyperactivity disorder. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Harrow FDA EventsOrganon & Co. FDA EventsActuate Therapeutics FDA EventsAlterity Therapeutics FDA EventsErnexa Therapeutics FDA EventsKymera Therapeutics FDA EventsMicrobot Medical FDA EventsPalisade Bio FDA EventsRedhill Biopharma FDA EventsScienture FDA EventsTG Therapeutics FDA EventsGenmab A/S FDA EventsMediciNova FDA EventsMetaVia FDA EventsNeurocrine Biosciences FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Veradermics FDA Events Travere Therapeutics FDA Events Erasca FDA Events NewAmsterdam Pharma FDA Events Catalyst Pharmaceuticals FDA Events Viking Therapeutics FDA Events Crinetics Pharmaceuticals FDA Events Kiniksa Pharmaceuticals International FDA Events ACADIA Pharmaceuticals FDA Events Edgewise Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:COLL last updated on 10/22/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersOpenAI is preparing to go publicOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredImportant SpaceX PREDICTIONThe biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...Banyan Hill Publishing | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Poster Presentation - October 22,2025Poster Presentation Drug: Jornay PMAnnounced Date: October 22, 2025Indication: for the treatment of attention deficit hyperactivity disorderAnnouncementCollegium Pharmaceutical, Inc announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neuroscience Education Institute (NEI) conferences.AI SummaryCollegium Pharmaceutical will present real-world data on its ADHD product Jornay PM at two conferences. One poster will appear at the American Academy of Child & Adolescent Psychiatry in Chicago (Oct 20–25). The other will be shown at the Neuroscience Education Institute Fall Congress in Colorado Springs (Nov 6–9). The AACAP poster explores optimal dosing of methylphenidate in adolescents and adults in real-world psychiatric settings. The NEI poster examines how patients use and respond to Jornay PM outside clinical trials. Thomas Smith, M.D., said these findings during ADHD Awareness Month highlight Collegium’s commitment to improving care. Researchers will share insights on dosing and patient response to this unique nighttime ADHD stimulant. The AACAP poster will be shown Oct 22, 4–6 p.m. CDT at the Hyatt Regency, and the NEI poster will be presented Nov 7, 4–5 p.m. MST at Broadmoor West.Read Announcement
Free COLL Stock Alerts